StockIQpro
NASDAQ:BOLT

Bolt Biotherapeutics, Inc.

Track all markets on TradingView
Track all markets on TradingView

Bolt Biotherapeutics, Inc.'s revenue grew 0.1% in fiscal 2025 to $7.7M while operating margin rose to −469.3%, its highest in 6 years. Free cash flow was −$39.9M, −518.8% of revenue, and the diluted share count fell 2.1%.Summary generated from Bolt Biotherapeutics, Inc.'s SEC filings. Latest annual report filed Mar 12, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)$7.7M
Revenue growth+0.1%
Revenue, 5-yr CAGR+101.6%
Gross marginn/a
Operating margin−469.3%
Net margin−433.7%
ROICn/a
Return on equity−79.7%
Debt / equityn/a
Free cash flow−$39.9M
FCF margin−518.8%
Share count change−2.1%

Financials

Fiscal years, $M
Item20212022202320242025
Revenue16888
Operating income−93−90−76−73−36
Net income−99−88−69−63−33
Free cash flow−59−78−70−61−40

Recent filings

From SEC EDGAR

Peers

Pharmaceutical preparations